GSK3A

Across TCGA pan-cancer cohorts, GSK3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSK3A data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSK3A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GSK3A expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where GSK3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
GBM	DFS	Quartile	All	0.950	0.634	.002	10	view →
HNSC	DFS	Quartile	II,III,IV	0.601	0.850	.030	3	view →
CCRCC	DFS	Quartile	III,IV	0.750	0.313	.034	2	view →
LSCC	DFS	Quartile	All	1.000	0.882	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSK3A–PDAC (DFS)

Open the PDAC breakdown →